spacer
home > ebr > spring 2018 > sudden impact
PUBLICATIONS
European Biopharmaceutical Review

Sudden Impact

The development of biological therapeutics such as humanised antibodies has led to remarkable clinical benefits in many indications. Despite this success, the induction of anti-drug antibodies (ADAs) due to the potential immunogenicity of these therapeutics remains a significant challenge to the successful development of biotherapeutics.

The decades that followed the approval of the first biotherapeutic (Insulin, 1982) have seen a dramatic increase in both the number and rate of approvals. Biologics now account for over 30% of licensed pharmaceutical products and over 25% of the new drugs approved by The Center for Drug Evaluation and Research in 2015. For monoclonal antibodies (mAbs) alone, since the commercialisation of the first mAb in 1986, this class of product has increased significantly. By 2014, 47 mAb products had been approved in the US and Europe. At the current approval rate, it can be anticipated that approximately 70 mAb products will be on the market by 2020, with combined worldwide sales of nearly US$125 billion (1).

Despite this success, biologics can elicit immunological responses when administered to patients, which can affect their safety and efficacy. These side effects fall into two categories: pharmacological (largely predictable adverse reactions resulting from the interaction between the biologic and its target) and non-pharmacological. Non-pharmacological adverse events contain immunotoxicity, which includes both immuneresponseand non-immune response-mediated reactions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Gary Bembridge is Senior Director of scientific affairs (immunology) at Abzena. Since joining the company in 2013, he has managed business development activities associated with immunological responses to biotherapeutics, ensuring that immunogenicity assessment and bespoke immunological studies are tailored to partnersí needs. Prior to this, Gary worked at Huntingdon Life Sciences (Envigo) as a Biopharmaceutical Product Development Manager and shared responsibility for designing safety studies and nonclinical development programmes for all biologics, providing scientific support and advice to the immunology department. He completed his PhD at the University of Bristol, UK, and the Department of Veterinary Medicine.

Dr Karen Hills is in marketing and business development at Abzena in Cambridge, UK. She is a consultant in pharma/biopharma business development and marketing. Since joining Abzena, Karen has focused on marketing across the areas of cell-line development, chemistry manufacturing, and immunology. Karen has a PhD in molecularb from Cambridge University, UK, and an MBA from the London Business School, UK. Her background includes sales, marketing, and business development for companies ranging from start-up biotech to Big Pharma.
spacer
Dr Gary Bembridge
spacer
spacer
spacer
Dr Karen Hills
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.

Medpace

Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >>

 
Industry Events

Outsourcing Clinical Trials Nordics 2018

30-31 October 2018, Copenhagen, Denmark

Following on from the success of the 2017 Outsourcing in Clinical Trials Nordics conference, Arena International is pleased to announce that the event will return for its 6th year in 2018. The 2018 event welcomes biopharmaceutical and medical device companies from across the Nordic region to share knowledge and challenges of outsourcing and clinical operations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement